---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-011878"
form_type: "8-K"
ticker: "SMTI"
cik: "0000714256"
company_name: "Sanara MedTech Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T14:04:51.167233+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sanara MedTech Q2 revenue up 28% to $25.8M; launches strategic review for Tissue Health Plus subsidiary

## Summary
- Net revenue $25.8M, up 28% YoY; net loss narrowed to $2.0M from $3.5M.
- Adjusted EBITDA $2.7M vs $0.6M in prior-year quarter.
- H1 2025: revenue $49.3M (+27%), net loss $5.5M, adjusted EBITDA $3.3M.
- Sanara Surgical segment H1 adjusted EBITDA $7.4M vs $2.5M; THP segment adjusted EBITDA -$4.1M vs -$1.6M.
- Company initiates process to evaluate strategic alternatives for Tissue Health Plus subsidiary.

## SEC filing metadata
- accession: 0001493152-25-011878
- form_type: 8-K
- ticker: SMTI
- cik: 0000714256
- company_name: Sanara MedTech Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/714256/000149315225011878/0001493152-25-011878-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/714256/000149315225011878/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-011878
- JSON: https://secwatch.observer/filing/0001493152-25-011878.json
- Plain text: https://secwatch.observer/filing/0001493152-25-011878.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.